Brokerages Set Revvity Inc. (NYSE:RVTY) Price Target at $114.77

Revvity Inc. (NYSE:RVTY) has received a consensus rating of “Hold” from the eighteen brokerages that are covering the stock, Marketbeat.com reports. Fourteen equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $116.5714.

A number of brokerages have recently issued reports on RVTY. Zacks Research upgraded Revvity from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Weiss Ratings upgraded Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 30th. UBS Group initiated coverage on Revvity in a report on Wednesday. They set a “neutral” rating and a $140.00 price target for the company. Wolfe Research began coverage on Revvity in a research note on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Finally, Wall Street Zen lowered Revvity from a “buy” rating to a “hold” rating in a report on Sunday, August 16th.

Revvity Price Performance

Shares of RVTY opened at $124.46 on Monday. The company’s 50-day moving average is $117.71 and its 200-day moving average is $103.21. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50. The firm has a market capitalization of $13.89 billion, a PE ratio of 59.27, a PEG ratio of 2.20 and a beta of 1.09. Revvity has a fifty-two week low of $81.22 and a fifty-two week high of $133.00.

Revvity (NYSE:RVTY) last announced its earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The business had revenue of $729.69 million during the quarter, compared to the consensus estimate of $702.96 million. During the same quarter in the previous year, the firm posted $1.18 EPS. Revvity’s revenue was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Equities analysts forecast that Revvity will post 5.36 EPS for the current year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. Revvity’s payout ratio is presently 13.33%.

Hedge Funds Weigh In On Revvity

Hedge funds have recently bought and sold shares of the business. Ascentis Independent Advisors acquired a new stake in Revvity in the 1st quarter worth about $29,000. CYBER HORNET ETFs LLC acquired a new position in shares of Revvity during the 2nd quarter worth approximately $32,000. MUFG Securities EMEA plc bought a new position in shares of Revvity during the second quarter worth approximately $34,000. SJS Investment Consulting Inc. increased its holdings in shares of Revvity by 5,210.0% during the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock worth $47,000 after purchasing an additional 521 shares during the period. Finally, Headlands Technologies LLC acquired a new stake in shares of Revvity in the second quarter valued at approximately $49,000. 86.65% of the stock is owned by institutional investors.

Revvity Company Profile

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer’s Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.